Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:35:43 2023-06-08 am EDT
95.44 EUR   +0.52%
05:20pPress Release : FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
GL
04:38pADRs End Higher, Innate Pharma and Medigus Trade Actively
DJ
04:21pUS FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/02/2023 06/05/2023 06/06/2023 06/07/2023 06/08/2023 Date
94.98(c) 95.33(c) 96.37(c) 94.95(c) 95.44(c) Last
1 285 713 861 053 1 302 000 1 144 216 872 656 Volume
+0.82% +0.37% +1.09% -1.47% +0.52% Change
More quotes
Estimated financial data (e)
Sales 2023 44 818 M 48 290 M 48 290 M
Net income 2023 8 019 M 8 641 M 8 641 M
Net Debt 2023 4 577 M 4 931 M 4 931 M
P/E ratio 2023 14,8x
Yield 2023 3,87%
Sales 2024 47 160 M 50 814 M 50 814 M
Net income 2024 9 089 M 9 793 M 9 793 M
Net cash position 2024 2 337 M 2 518 M 2 518 M
P/E ratio 2024 13,1x
Yield 2024 4,08%
Capitalization 119 B 128 B 128 B
EV / Sales 2023 2,76x
EV / Sales 2024 2,48x
Nbr of Employees 91 573
Free-Float 88,2%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.4%): prescription drugs in the areas of specialty medicine (54.7% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (45.3%; mainly... 
Read more
Sector
Pharmaceuticals
Calendar
06/14 | 01:00pmPresentation
More about the company
Ratings of Sanofi
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SANOFI
05:20pPress Release : FDA Advisory Committee unanimously recommends nirsevimab as first immuniza..
GL
04:38pADRs End Higher, Innate Pharma and Medigus Trade Actively
DJ
04:21pUS FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
RE
04:10pUS FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy
RE
12:35pEmployment Growth Pushes French Bourse Higher Despite Eurozone's Technical Recession
MT
10:39aInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track Designation
DJ
04:49aSanofi, Innate Pharma's Blood Cancer Therapy Wins Fast Track Status in US
MT
06/07US FDA Staff Notes Safety, Efficacy of Sanofi-AstraZeneca's RSV Jab Ahead of Advisory P..
MT
06/06U.S. Supreme Court Affirmed Patent Enablement Requirement In Amgen
AQ
06/05Sobi to present new data at the 2023 EHA congress
AQ
06/02Media Update : New data from Sanofi's diverse, differentiated oncology pipeline and portfo..
PU
06/01European Equities Recover Some Losses in Thursday Trading
MT
06/01US FDA approves Pfizer RSV vaccine a month after greenlighting GSK shot
RE
06/01Supreme Court Affirms High Enablement Bar For Drug Patents
AQ
06/01Press Release : Sanofi launches 2023 global Employee Stock Purchase Plan  
GL
More news
News in other languages on SANOFI
05:53pUn panel en EEUU respalda terapia preventiva de Sanofi-AstraZeneca contra el virus sinc..
05:20pCommuniqué De Presse : Le Comité consultatif de la FDA recommande le nirsevimab à l'unanim..
12:35pLa croissance de l'emploi pousse la bourse française à la hausse malgré la récession te..
04:49aLe traitement du cancer du sang de Sanofi et Innate Pharma obtient le statut de procédu..
03:08aSanofi : obtient le statut Fast Track pour un traitement
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 06/07
In an accumulation phase
BUY
More Stock Trading Analysis
ETFs positioned on SANOFIETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
BNP Paribas Easy CAC 40 ESG - EUR8.46%1.58%-NC
AMUNDI CAC 40 ESG DR - EUR (C)8.31%1.43%-NC
AMUNDI CAC 40 ESG DR - EUR (D)8.31%1.71%-NC
Xtrackers MSCI Europe Health Care ESG Scree...7.97%1.03%-NC
IShares MSCI Europe Health Care Sector Acc - EUR7.76%0.82%-NC
More ETFs positioned on SANOFI
Analysis
All about credit ratings
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 95,44 €
Average target price 110,48 €
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Frédéric Oudéa Chairman
Nestle Frank Global Head-Immunology Therapeutic Research Area
Dietmar P. Berger Chief Medical Officer & Global Head-Development
Sector and Competitors
1st jan.Capi. (M$)
SANOFI5.69%126 946
JOHNSON & JOHNSON-10.46%443 455
ELI LILLY AND COMPANY19.28%414 234
NOVO NORDISK A/S16.42%351 939
MERCK & CO., INC.-2.11%275 591
ROCHE HOLDING AG-0.91%256 071
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer